Hence, the NEAT1/miR-504/SMO axis deserves a closer look, especially since the downregulation of NEAT1 alleviated HCC hallmarks in vitro, which promotes NEAT1 as a valuable molecular target for HCC treatments [222]. The gene discussed is SMO; the disease is hepatocellular carcinoma.